Glaxo is investing $200M in additions to its U.K. site

Gsk is placing a huge emphasis on its manufacturing arm with plans to invest millions in their manufacturing projects. The company has announced that they will be dedicating approximately two-third of their upgrading funds to the production facility of Augmentin, Gsk’s leading antibody drug, at its Worthing site. Some funds will also be invested in Ware to build a plant for the manufacturing of its new generation Relvar Ellipta inhaler. However, the main highlight would be its first new manufacturing facility in the U.K in 40 years.

These investments are expected to bring about cost-saving and efficient manufacturing processes for GSK. The release of this news will also signify the security of GSK employees’ future.
You may read more at: http://www.fiercepharmamanufacturing.com/story/glaxo-investing-200m-additions-uk-site/2014-01-23#ixzz2riTDpUOI

Comments 1

  1. Dawn

    You state “dedicating approximately two-third of their upgrading funds to the production facility of Augmentin, Gsk’s leading antibody drug, at its Worthing site.” Augmentin is not an antibody drug as stated – it is actually amoxicillin/clavulanic acid.

Leave a Reply

Your email address will not be published. Required fields are marked *